What are the differences between ER alpha and ER beta?
In particular, ERα is highly expressed in endothelial cells and plays a role in mediating the effects of estrogens in the vascular endothelium, whereas ERβ stimulates the production of nitric oxide.
What is estrogen receptor antagonist?
Estrogen receptor antagonists bind to estrogen receptors and inhibit the action of estrogen. Estrogen controls the growth of certain types of breast cancers called estrogen receptor positive cancers. So estrogen receptor antagonists are useful in treating patients with estrogen sensitive breast cancers.
What are SERM drugs?
A: SERMs stands for “selective estrogen receptor modulators,” also called estrogen agonists/antagonists, which describes what these drugs do. They activate or block the estrogen receptors only in certain areas of the body and not others. That can make them safer than estrogen alone or result in fewer side effects.
How does an antagonist bind to estrogen receptor?
Estrogen receptor antagonists inhibit transcription by promoting the binding of co-repressors (CoRs) to the ERE. CoRs inhibit transcription. The SERMs are partial agonists, antagonizing the effects of estrogen in some tissues (breast) and stimulating estrogen receptors in others (bone, brain, liver).
Which drug is classified as an estrogen agonist antagonist?
A first generation nonsteroidal selective estrogen receptor modulator used to treat certain breast cancers….Estrogen Agonist/Antagonist.
| Drug | Target | Type |
|---|---|---|
| Toremifene | Sex hormone-binding globulin | target |
| Tamoxifen | Estrogen receptor alpha | target |
| Tamoxifen | Estrogen receptor beta | target |
What are examples of SERMs?
Two of the most common SERMs are tamoxifen (Nolvadex, Soltamox) and raloxifene (Evista). There are several others as well, including lasofoxifene, bazedoxifene, and clomiphene citrate. Keep reading to learn more about the types of SERMs and how they work to treat different conditions.
Why is tamoxifen a SERM?
Three agents are available that act as SERMs: tamoxifen, raloxifene, and toremifene [1]. All three agents are competitive inhibitors of estrogen binding to estrogen receptors (ERs), and all have mixed agonist and antagonist activity, depending on the target tissue.
What is the difference between tamoxifen and aromatase inhibitors?
For women with early-stage oestrogen receptor (ER)-positive breast cancer, adjuvant tamoxifen reduces 15-year breast cancer mortality by a third. Aromatase inhibitors are more effective than tamoxifen in postmenopausal women but are ineffective in premenopausal women when used without ovarian suppression.
Why is tamoxifen an antagonist?
In breast tissue, tamoxifen acts as an ER antagonist so that transcription of estrogen-responsive genes is inhibited. A beneficial side effect of tamoxifen is that it prevents bone loss by acting as an ER agonist (i.e., mimicking the effects of estrogen) in this cell type.
Why is tamoxifen an agonist and antagonist?
If a cell type requires activating factors 1 and 2 of the estrogen receptor to be functioning concurrently, tamoxifen is antagonistic. However, if a cell or tissue requires only activating factor 1 to interact with transcription factors at the promoter, tamoxifen is agonistic.
When are SERMs used?
Selective estrogen receptor modulators (SERMs) are now being used as a treatment for breast cancer, osteoporosis and postmenopausal symptoms, as these drugs have features that can act as an estrogen agonist and an antagonist, depending on the target tissue.
Is tamoxifen a competitive antagonist?
Currently available antioestrogens, such as tamoxifen, are competitive inhibitors that bind to the ligand binding sites of oestrogen receptors, ERalpha and ERbeta. The search for alternative anti-hormone therapies is prompted by the need for drugs that are effective when tumours become tamoxifen resistant.
Why is tamoxifen a mixed antagonist?
The dual action is a function of the estrogen receptor complex present in a particular cell or tissue. If a cell type requires activating factors 1 and 2 of the estrogen receptor to be functioning concurrently, tamoxifen is antagonistic.
Does Erer (alpha)-selective antagonism exist on diverse reporter-promoter gene constructs?
ER (alpha)-selective antagonism was observed on diverse reporter-promoter gene constructs containing estrogen response elements that are consensus, nonconsensus (pS2), or comprised of multiple half-estrogen response elements (NHERF/EBP50) and on genes in which ER works indirectly by tethering to other DNA-bound proteins (TGF (beta)3).
Are selective ER α antagonists helpful for the treatment of breast cancer?
The newly developed antiestrogens should not only have good binding affinity with particular receptor but it also must have selective activation for that receptor which expressed in breast cancer progression. Therefore, selective ER α antagonists may be helpful for the breast cancer treatment [ 10 ].
What is estrogen receptor alpha (ERα)?
From Wikipedia, the free encyclopedia Estrogen receptor alpha (ERα), also known as NR3A1 (nuclear receptor subfamily 3, group A, member 1), is one of two main types of estrogen receptor, a nuclear receptor that is activated by the sex hormone estrogen. In humans, ERα is encoded by the gene ESR1 (EStrogen Receptor 1).
Is h3b-5942 a selective estrogen receptor covalent antagonist?
Through our drug-discovery efforts, we identified H3B-5942, which covalently inactivates both wild-type and mutant ERα by targeting Cys530 and enforcing a unique antagonist conformation. H3B-5942 belongs to a class of ERα antagonists referred to as selective estrogen receptor covalent antagonists (SERCA).